Results 191 to 200 of about 1,023,593 (296)

Dynamic capture enabled by sequential phase-switching adhesion. [PDF]

open access: yesSci Adv
Li R   +9 more
europepmc   +1 more source

Considerations for Issues of Regression to the Mean and Contextual Effects in Clinical Trials for Pain in Rheumatic Diseases

open access: yesArthritis Care &Research, EarlyView.
Recently, there has been growing discussion about how to best assess pain in clinical trials in rheumatic diseases. Reliable measurement of pain outcomes is essential for accurately determining the effectiveness of treatments. Although pain intensity is the most common measure of change in pain trials, other pain‐related measures, such as pain ...
Yen T. Chen   +4 more
wiley   +1 more source

Perceptions about asymptomatic hyperuricemia and views about urate‐lowering therapy in people with asymptomatic hyperuricemia

open access: yesArthritis Care &Research, Accepted Article.
Background/Aims Asymptomatic hyperuricemia is a precursor of gout and is also associated with cardiovascular disease and chronic kidney disease. The aim of this study was to understand perceptions about asymptomatic hyperuricemia and views about urate‐lowering therapy in people with asymptomatic hyperuricemia.
Nicola Dalbeth   +19 more
wiley   +1 more source

Assessment of Pain Types in Recently Diagnosed Patients With Inflammatory Arthritis

open access: yesArthritis Care &Research, EarlyView.
Objective Up to 40% of patients with inflammatory arthritis (IA) experience persistent pain, traditionally thought to be associated with a shift from peripherally to centrally mediated pain during the disease course in some patients. We assessed sensory profiles of recently diagnosed individuals with IA, hypothesizing that pain reported at this early ...
Zoe Rutter‐Locher   +8 more
wiley   +1 more source

Serum soluble mediator signatures of lupus nephritis: histological features and response to treatment

open access: yesArthritis Care &Research, Accepted Article.
Objective Lupus nephritis (LN) management remains challenging, and novel noninvasive biomarkers are needed. This study quantified serum soluble mediators in the Accelerating Medicines Partnership (AMP) LN cohort to identify biomarkers of histological features and treatment response.
Andrea Fava   +26 more
wiley   +1 more source

Home - About - Disclaimer - Privacy